Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients

Published:2023-02-22 Issue:7 Volume:72 Page:1957-1969
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Han Cheng-Long,Tian Bao-Wen,Yan Lun-Jie,Ding Zi-Niu,Liu Hui,Mao Xin-Cheng,Tian Jin-Cheng,Xue Jun-Shuai,Tan Si-Yu,Dong Zhao-Ru,Yan Yu-Chuan,Hong Jian-Guo,Chen Zhi-Qiang,Wang Dong-Xu,Li Tao

Funder

Taishan Scholars Program of Shandong Province

National Natural Science Foundation of China

Major basic research of Shandong Provincial Natural Science Foundation

funds for Independent Cultivation of Innovative Team from Universities in Jinan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-023-03390-x.pdf

Reference76 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

2. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7(1):6. https://doi.org/10.1038/s41572-020-00240-3

3. Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M et al (2018) Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis. JAMA Oncol 4(4):522–528. https://doi.org/10.1001/jamaoncol.2017.5236

4. Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223–249. https://doi.org/10.1146/annurev-pathol-042020-042741

5. Seliger B (2019) The role of the lymphocyte functional crosstalk and regulation in the context of checkpoint inhibitor treatment-review. Front Immunol 10:2043. https://doi.org/10.3389/fimmu.2019.02043

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy comparison of immune combination therapies in subgroups for advanced hepatocellular carcinoma patients: Systematic review and network meta-analysis;PLOS ONE;2024-07-22

2. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective;eClinicalMedicine;2024-04

3. Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma;Frontiers in Immunology;2023-12-22

4. External validation of subclassification system and progression pattern analysis in hepatocelluar carcinoma with macroscopic vascular invasion;Radiotherapy and Oncology;2023-10

5. Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition;Cancer Cell International;2023-09-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3